Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01165983 · ClinicalTrials.gov registry record · NA
The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 124
- Enrollment target
NCT01165983 is a NA study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 124 participants.
The verdict
NCT01165983, a NA study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of this research is to study and determine the effects of Aliskiren on blood vessels and blood flow. The primary hypothesis is that Aliskiren will increase endothelial function by 30% or more in comparison to the placebo group.
Interventions
- DRUG Placebo
- DRUG Aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2009-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01165983
The ClinicalTrials.gov registry entry for NCT01165983 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01165983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01165983 about?
NCT01165983 is a clinical study titled "The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes". The purpose of this research is to study and determine the effects of Aliskiren on blood vessels and blood flow. The primary hypothesis is that Aliskiren will increase endothelial function by 30% or more in comparison to the placebo group.
What is the current status of trial NCT01165983?
This trial is currently completed. It is a NA study. The enrollment target is 124 participants. The study started on 2009-11.
What interventions are being tested in trial NCT01165983?
The interventions under investigation include: Placebo (DRUG), Aliskiren (DRUG).
Who is sponsoring clinical trial NCT01165983?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.